相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。PCSK9 Inhibition During the Inflammatory Stage of SARS-CoV-2 Infection
Eliano P. Navarese et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2023)
Plasma PCSK9 levels and sepsis severity: an early assessment in the emergency department
Francesca Innocenti et al.
CLINICAL AND EXPERIMENTAL MEDICINE (2021)
PCSK9 inhibitors for COVID-19: an opportunity to enhance the antiviral action of interferon in patients with hypercholesterolaemia
A. Vuorio et al.
JOURNAL OF INTERNAL MEDICINE (2021)
Alirocumab treatment and neurocognitive function according to the CANTAB scale in patients at increased cardiovascular risk: A prospective, randomized, placebo-controlled study
Matthew J. Janik et al.
ATHEROSCLEROSIS (2021)
Evolocumab in HIV-Infected Patients With Dyslipidemia Primary Results of the Randomized, Double-Blind BEIJERINCK Study
Franck Boccara et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2020)
Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?
Lei Fang et al.
LANCET RESPIRATORY MEDICINE (2020)
Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol
Kausik K. Ray et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia
Frederick J. Raal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
May statins and PCSK9 inhibitors be protective from COVID-19 in familial hypercholesterolemia subjects?
Roberto Scicali et al.
NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES (2020)
Dengue virus induces PCSK9 expression to alter antiviral responses and disease outcomes
Esther Shuyi Gan et al.
JOURNAL OF CLINICAL INVESTIGATION (2020)
PCSK9: A Potential Therapeutic Target for Sepsis
Yuan Yuan et al.
JOURNAL OF IMMUNOLOGY RESEARCH (2020)
Long-term impact of sepsis on cardiovascular health
R. T. Mankowski et al.
INTENSIVE CARE MEDICINE (2019)
A systematic review on risk factors associated with sepsis in patients admitted to intensive care units
Mohammad Fathi et al.
AUSTRALIAN CRITICAL CARE (2019)
Adverse Events Associated With PCSK9 Inhibitors: A Real-World Experience
Muhammed T. Gurgoze et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2019)
Study of serious adverse drug reactions using FDA-approved drug labeling and MedDRA
Leihong Wu et al.
BMC BIOINFORMATICS (2019)
Randomised study of evolocumab in patients with type 2 diabetes and dyslipidaemia on background statin: Primary results of the BERSON clinical trial
Alberto J. Lorenzatti et al.
DIABETES OBESITY & METABOLISM (2019)
Efficacy and safety of evolocumab in individuals with type 2 diabetes mellitus: primary results of the randomised controlled BANTING study
Robert S. Rosenson et al.
DIABETOLOGIA (2019)
Reduced Proprotein convertase subtilisin/kexin 9 (PCSK9) function increases lipoteichoic acid clearance and improves outcomes in Gram positive septic shock patients
Alex K. K. Leung et al.
SCIENTIFIC REPORTS (2019)
A Genetic Approach to the Association Between PCSK9 and Sepsis
QiPing Feng et al.
JAMA NETWORK OPEN (2019)
PCSK9 and infection: A potentially useful or dangerous association?
Farzad Khademi et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2018)
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
G. G. Schwartz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Impact of PCSK9 loss-of-function genotype on 1-year mortality and recurrent infection in sepsis survivors
Kelly Roveran Genga et al.
EBIOMEDICINE (2018)
PCSK9 inhibitors in sepsis: a new potential indication?
Amir Abbas Momtazi et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2017)
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Marc S. Sabatine et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Recognizing Sepsis as a Global Health Priority - A WHO Resolution
Konrad Reinhart et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol
Kausik K. Ray et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta-Analysis of 35 Randomized Controlled Trials
Aris Karatasakis et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2017)
Efficacy and safety of alirocumab in insulin-treated individuals with type 1 or type 2 diabetes and high cardiovascular risk: The ODYSSEY DM-INSULIN randomized trial
Lawrence A. Leiter et al.
DIABETES OBESITY & METABOLISM (2017)
A Phase 3 Study of Evolocumab (AMG 145) in Statin-Treated Japanese Patients at High Cardiovascular Risk
Arihiro Kiyosue et al.
AMERICAN JOURNAL OF CARDIOLOGY (2016)
A phase III randomized trial evaluating alirocumab 300 mg every 4 weeks as monotherapy or add-on to statin: ODYSSEY CHOICE I
Eli M. Roth et al.
ATHEROSCLEROSIS (2016)
Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients The GLAGOV Randomized Clinical Trial
Stephen J. Nicholls et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
Increased Plasma PCSK9 Levels Are Associated with Reduced Endotoxin Clearance and the Development of Acute Organ Failures during Sepsis
John H. Boyd et al.
JOURNAL OF INNATE IMMUNITY (2016)
Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: The ODYSSEY COMBO I study
Dean J. Kereiakes et al.
AMERICAN HEART JOURNAL (2015)
Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
Jennifer G. Robinson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Preventing Cardiovascular Complications of Acute Infection A Missed Opportunity?
Allan J. Walkey
CIRCULATION (2014)
Effect of Evolocumab or Ezetimibe Added to Moderate- or High-Intensity Statin Therapy on LDL-C Lowering in Patients With Hypercholesterolemia The LAPLACE-2 Randomized Clinical Trial
Jennifer G. Robinson et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2014)
A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia
Dirk J. Blom et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
PCSK9 is a critical regulator of the innate immune response and septic shock outcome
Keith R. Walley et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Acute pneumonia and the cardiovascular system
Vicente F. Corrales-Medina et al.
LANCET (2013)
The impact of diabetes on the pathogenesis of sepsis
G. C. K. W. Koh et al.
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES (2012)
Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study
Robert P. Giugliano et al.
LANCET (2012)
The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration
Alessandro Liberati et al.
BMJ-BRITISH MEDICAL JOURNAL (2009)
分享论文
